Market Overview:
The global oncology biomarker market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth of the market can be attributed to the increasing incidence of cancer, rising demand for early diagnosis and treatment, and technological advancements in biomarker assay development. Based on type, the global oncology biomarker market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, and others. The lung cancer segment is expected to account for the largest share of the global oncology biomarkers market in 2018. This can be attributed to factors such as increasing incidence of lung cancers across the globe and growing awareness about early detection and treatment options for lung cancers. Based on application, the global oncology biomarkers market is segmented into diagnostics; drug discovery & development; prognostics; risk assessment; and others (tumor biology research & clinical trials). The diagnostics segment accounted for the largest share of this market in 2017 owing to rising demand for accurate diagnosis of various types of cancers at an early stage.
Product Definition:
A biomarker is a measurable indicator of the presence, activity, or progress of a particular process. In oncology, biomarkers are used to detect cancer and track its progression. They can also be used to identify patients who are likely to respond favorably to certain treatments and help researchers develop new therapies.
Lung Cancer:
Lung cancer is a type of cancer that begins in the lung tissues and bronchus. The most common types of lung cancers are non-small cell lung carcinoma (NSCLC), small cell lung carcinoma (SCLC) and combined small & non-small cell Lung carcinoma (CSNL). Lung Cancer generally has two types, namely Small Cell Lymphoma or Large B-cell Lymphoma.
Breast Cancer:
Breast cancer is a malignant tumor that develops in the milk ducts of the breast. It is one of the most common types of cancer among women, after skin melanoma. Breast cancer has different stages and grades which can be differentiated by degree of invasiveness and distance from lymph nodes (Nodes are collections of cells that serve as sentinels for detecting abnormal growth).
Application Insights:
Risk assessment dominated the global oncology biomarker market in terms of revenue in 2017. This is due to its wide application across cancer types, which includes tumor stratification and risk estimation for developing a disease. Moreover, rising prevalence of cancer as well as increasing demand for risk estimation tools are expected to propel the segment growth during the forecast period.
Oncology biomarkers have numerous applications such as diagnostics, drug discovery & development and prognosis in various fields such as solid tumors, blood disorders and hematological malignancies among others. Diagnostic oncology holds a significant share owing to high usage across multiplexes genomic testing procedures that assist medical professionals with accurate diagnosis at an early stage along with improved treatment options for patients suffering from cancerous conditions.
Regional Analysis:
North America dominated the global oncology biomarker market in 2017. This can be attributed to the presence of key players, increased funding for cancer research and development, and rising prevalence of cancer in this region. The U.S.-based companies are engaged in extensive R&D activities related to biomarkers that can be used for diagnosis as well as treatment of various cancers.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing focus of major pharmaceutical companies on this region due to availability of skilled labor at a low cost along with easy access to raw materials such as herbs and spices used for manufacturing medicines. Moreover, Asian countries have a huge base of herbal medicine which is being increasingly utilized for treating various types chronic diseases including cancer; these factors are anticipated contribute towards regional growth during the forecast period (2018-2030).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for oncology biomarker market. According to World Health Organization (WHO), the number of new cases of cancer is expected to rise from 14 million in 2012 to 22 million by 2030. This will create a huge demand for oncology biomarkers, which will help in early diagnosis and treatment of cancer patients.
- Rising awareness about benefits of early diagnosis: There is a growing awareness among people about the benefits of early diagnosis and treatment for various diseases including cancer. This is driving the demand for oncology biomarkers, which can help in early detection and treatment of cancers.
- Technological advancements: The technological advancements are helping in development and commercialization of novel oncology biomarkers that are more accurate, sensitive, specific and less time consuming than traditional methods used for diagnosing cancers such as biopsy or histopathology examination etcetera .This is propelling the growth prospects for global oncology biomarker market during forecast period 2016-2022 .
Scope Of The Report
Report Attributes
Report Details
Report Title
Oncology Biomarker Market Research Report
By Type
Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others
By Application
Diagnostics, Drug Discovery And Development, Prognostics, Risk Assessment, Others
By Companies
Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Genomic Health, GlaxoSmithKline plc, Novartis AG, Merck & Co., Pfizer, Qiagen N.V.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
201
Number of Tables & Figures
141
Customization Available
Yes, the report can be customized as per your need.
Global Oncology Biomarker Market Report Segments:
The global Oncology Biomarker market is segmented on the basis of:
Types
Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diagnostics, Drug Discovery And Development, Prognostics, Risk Assessment, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- F.Hoffmann-La Roche Ltd.
- Genomic Health
- GlaxoSmithKline plc
- Novartis AG
- Merck & Co.
- Pfizer
- Qiagen N.V.
Highlights of The Oncology Biomarker Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Others
- By Application:
- Diagnostics
- Drug Discovery And Development
- Prognostics
- Risk Assessment
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oncology Biomarker Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A biomarker is a biological indicator of disease or health. In oncology, biomarkers are used to identify cancer cells and track their progress or response to treatment.
Some of the key players operating in the oncology biomarker market are Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Genomic Health, GlaxoSmithKline plc, Novartis AG, Merck & Co., Pfizer, Qiagen N.V..
The oncology biomarker market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oncology Biomarker Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oncology Biomarker Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oncology Biomarker Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oncology Biomarker Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oncology Biomarker Market Size & Forecast, 2018-2028
4.5.1 Oncology Biomarker Market Size and Y-o-Y Growth
4.5.2 Oncology Biomarker Market Absolute $ Opportunity
Chapter 5 Global Oncology Biomarker Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Oncology Biomarker Market Size Forecast by Type
5.2.1 Lung Cancer
5.2.2 Breast Cancer
5.2.3 Colorectal Cancer
5.2.4 Prostate Cancer
5.2.5 Stomach Cancer
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Oncology Biomarker Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Oncology Biomarker Market Size Forecast by Applications
6.2.1 Diagnostics
6.2.2 Drug Discovery And Development
6.2.3 Prognostics
6.2.4 Risk Assessment
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oncology Biomarker Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oncology Biomarker Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Oncology Biomarker Analysis and Forecast
9.1 Introduction
9.2 North America Oncology Biomarker Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Oncology Biomarker Market Size Forecast by Type
9.6.1 Lung Cancer
9.6.2 Breast Cancer
9.6.3 Colorectal Cancer
9.6.4 Prostate Cancer
9.6.5 Stomach Cancer
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Oncology Biomarker Market Size Forecast by Applications
9.10.1 Diagnostics
9.10.2 Drug Discovery And Development
9.10.3 Prognostics
9.10.4 Risk Assessment
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Oncology Biomarker Analysis and Forecast
10.1 Introduction
10.2 Europe Oncology Biomarker Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Oncology Biomarker Market Size Forecast by Type
10.6.1 Lung Cancer
10.6.2 Breast Cancer
10.6.3 Colorectal Cancer
10.6.4 Prostate Cancer
10.6.5 Stomach Cancer
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Oncology Biomarker Market Size Forecast by Applications
10.10.1 Diagnostics
10.10.2 Drug Discovery And Development
10.10.3 Prognostics
10.10.4 Risk Assessment
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Oncology Biomarker Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Oncology Biomarker Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Oncology Biomarker Market Size Forecast by Type
11.6.1 Lung Cancer
11.6.2 Breast Cancer
11.6.3 Colorectal Cancer
11.6.4 Prostate Cancer
11.6.5 Stomach Cancer
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Oncology Biomarker Market Size Forecast by Applications
11.10.1 Diagnostics
11.10.2 Drug Discovery And Development
11.10.3 Prognostics
11.10.4 Risk Assessment
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Oncology Biomarker Analysis and Forecast
12.1 Introduction
12.2 Latin America Oncology Biomarker Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Oncology Biomarker Market Size Forecast by Type
12.6.1 Lung Cancer
12.6.2 Breast Cancer
12.6.3 Colorectal Cancer
12.6.4 Prostate Cancer
12.6.5 Stomach Cancer
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Oncology Biomarker Market Size Forecast by Applications
12.10.1 Diagnostics
12.10.2 Drug Discovery And Development
12.10.3 Prognostics
12.10.4 Risk Assessment
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Oncology Biomarker Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Oncology Biomarker Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Oncology Biomarker Market Size Forecast by Type
13.6.1 Lung Cancer
13.6.2 Breast Cancer
13.6.3 Colorectal Cancer
13.6.4 Prostate Cancer
13.6.5 Stomach Cancer
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Oncology Biomarker Market Size Forecast by Applications
13.10.1 Diagnostics
13.10.2 Drug Discovery And Development
13.10.3 Prognostics
13.10.4 Risk Assessment
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oncology Biomarker Market: Competitive Dashboard
14.2 Global Oncology Biomarker Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Bristol-Myers Squibb
14.3.3 Eli Lilly and Company
14.3.4 F.Hoffmann-La Roche Ltd.
14.3.5 Genomic Health
14.3.6 GlaxoSmithKline plc
14.3.7 Novartis AG
14.3.8 Merck & Co.
14.3.9 Pfizer
14.3.10 Qiagen N.V.
